3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

# **Product Information**

#### Anti-PGC-1a

produced in rabbit, affinity isolated antibody

Product Number SAB4200209

## **Product Description**

Anti-PGC-1 $\alpha$  is produced in rabbit using as the immunogen a synthetic peptide corresponding to a fragment of mouse PGC-1 $\alpha$  (GeneID 19017), conjugated to KLH. The corresponding sequence is identical in rat PGC-1 $\alpha$  and highly conserved (single amino acid substitution) in human PGC-1 $\alpha$ . The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-PGC-1 $\alpha$  specifically recognizes human PGC-1 $\alpha$ . The antibody can be used in several immunochemical techniques including immunoblotting (~120 kDa). Detection of the PGC-1 $\alpha$  band by immunoblotting is specifically inhibited by the PGC-1 $\alpha$  immunizing peptide.

PGC-1 $\alpha$  (also known as PPARGC1A) is a master transcriptional coactivator that integrates and regulates several metabolic pathways in response to external stimuli. PGC-1α regulates adaptive thermogenesis in brown adipose tissue and insulin signaling in skeletal muscle by activation of central metabolic and energyrelated genes. PGC-1 $\alpha$  has a central role in the regulation of liver gluconeogenesis, β-oxidation of fatty acids and ketogenesis, by coactivation of key enzymes in the metabolic pathway, indicating that PGC-1 $\alpha$  plays an important role as a global regulator of liver metabolism during fasting.<sup>2-5</sup> PGC-1 $\alpha$  interacts with and coactivates a variety of nuclear receptors (NRs), such as the glucocorticoid receptor (GR), HNF4 $\alpha$ , and PPARs in various tissues.  $^{1,2}$  PGC- $1\alpha$  is also a potent activator of mitochondrial biogenesis resulting by coactivation of ERR $\alpha$ , NRF-1, and NRF-2. PGC-1 $\alpha$  has been shown to suppress the generation of ROS and neurodegeneration by protecting neuronal cells from oxidative stress-mediated death.6 PGC-1a knockout mice show increased sensitivity to damage by oxidative stress affecting neurons in the substantia nigra and hippocampus. Reductions in the expression levels of PGC-1 $\alpha$  in muscle has been implicated in the pathogenesis of type-2 diabetes.<sup>7,8</sup> PGC-1 $\alpha$  has been proposed to control muscle plasticity, to suppress broad inflammatory response, and to mediate the beneficial aspects of exercise.8

## Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Antibody concentration: ~1.5 mg/mL

#### **Precautions and Disclaimer**

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

# Storage/Stability

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify by centrifugation. Discard working dilutions if not used within 12 hours.

#### **Product Profile**

 $\frac{Immunoblotting}{Immunoblotting}: a working antibody concentration of 1-2 \ \mu g/mL is recommended using extracts of HEK-293T cells overexpressing human PGC-1 \( \alpha \).$ 

<u>Note</u>: In order to obtain best results in various techniques and preparations, it is recommended to determine optimal working dilutions by titration.

#### References

- 1. Puigserver, P., et al., Cell, 92, 829-839 (1998).
- 2. Lin, J., et al., Cell. Metab., 1, 361-370 (2005).
- 3. Yoon, J.C., et al., Nature, 413, 131-138 (2001).
- 4. Puigserver, P., et al., *Nature*, **423**, 550-555 (2003).
- 5. Li, X., et al., Nature, 447, 1012-1016 (2007).
- St-Pierre, J., et al., Cell, 127, 397-408 (2006).
- Pagel-Langenickel, I., et al., J. Biol. Chem., 283, 22464-22472 (2008).
- 8. Handschin, C., and Spiegelman, B., *Nature*, **454**, 463-469 (2008).

VS,ER,RC,KAA,PHC,MAM 07/19-1